Background: Thyroid function regulates a wide array of metabolic parameters. Thyroid function significantly affects lipoprotein metabolism as well as some cardiovascular disease (CVD) risk factors, thus influencing overall CDV risk.
Methods: A cross sectional study has been conducted to assess the association of subclinical hypothyroidism and overt hypothyroidism with lipid abnormalities.
Results: Serum HDL cholesterol in group A was 37.97±7.97 mg/dl, that in group B was 37.62±6.67 mg/dl, while in group C it was 36.27±5.79 mg/dl. Serum LDL cholesterol in group A was 150.9±29.70 mg/dl, that in group B was 115.2±22.02 mg/dl, while in group C it was 93.07±19.88 mg/dl. Serum total cholesterol in group A was 223±32.69 mg/dl, that in group B was 179.67±27.50 mg/dl, while in group C it was 152.4±21.47 mg/dl. Serum VLDL cholesterol in group A was 34.12±11.06 mg/dl, that in group B was 26.85±4.01 mg/dl, while in group C it was 23.05±3.09 mg/dl. Serum VLDL cholesterol in group A was 167.42±47.83 mg/dl, that in group B was 134.37±20.22 mg/dl, while in group C it was 115.17±15.66 mg/dl.
Conclusion: Thyroid dysfunction can have an important effect on lipid profile. Biochemical screening for thyroid dysfunction is critical in all dyslipidemic patients, as well as in all patients with unexpected improvement or worsening of their lipid profile.
Keywords: LDL,HDL,Cholesterol.
Background: Triple negative breast cancers (TNBC), a pathologically high grade subset of tumours has increasing prevalence in Indian population. Since their morphological features resemble with BRCA1 mutated inherited breast cancer, the present study was aimed to define the role of BRCA1 mutation in sporadic breast cancer. Aims and Objectives: 1. To evaluate immunohistochemical expression of BRCA-1 in non familial breast cancer cases and to correlate with clinical and histopathological parameters. Setting and Design: Prospective & Retrospective study (August 2014-August 2015). Tertiary care hospital in North Eastern India Materials and Methods: 189 cases of suspected breast cancer cases were included in the study. ER/PR/HER2 status was evaluated of 114 cases and molecular classification along with BRCA1 expression was seen in 62 patients. Statistical analysis: SPSS (Statistical Package for Social Sciences) Version 15.0 statistical Analysis Software. The values were represented in Number (%) and Mean±SD.Result: 71.56% of cases belonged to Nottingham's grade II and III. Among our groups maximum percentage were of TNBC (basal + non basal) and Her2 enriched i.e (30.6% respectively) followed by luminal B (24.2%) and luminal A (9.6%). 50% of cases in study sub population showed BRCA 1 loss. BRCA1 expression was nuclear and cytoplasmic in both control and cases. Maximum mean BRCA1 loss was seen in basal like, followed by triple negative non basal like, her2 enriched and minimum in luminal A. Conclusion: Large percentage of TNBC, increased BRCA1 expression loss and high grade, indicates need to fulfil the vacant space of therapeutic modality in TNBC management. PARP inhibitors, the future of therapeutic management of TNBC might also be helpful in sporadic cases of breast cancer exhibiting BRCA1 expression loss.
Kikuchi-Fujimoto disease (KFD) or histiocytic necrotizing lymphadenitis is a rare, benign, self-limiting disease with unknown etiology characterized by regional lymphadenopathy. A 30-year-old female presented with fever, weakness, multiple joint pain, oral ulcers, erythematous facial rashes, hemorrhagic crusting on both lips, and cervical lymphadenopathy of 2-month duration. Clinically, the disease was mimicking systemic lupus erythematosus, but immunofluorescence was negative for it. Lymph node biopsy suggested a diagnosis of KFD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.